[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fdw8YB_bj-65dwWptqQeP0qH4ZgMJAlpr_yk8wSviw9Q":8,"$frgSMDb3G9r_JYbTXi7-1Dm8ZPf5XVbTtNYq76hObI8c":55,"$fMjzUcK1HMUHjxJCC53uDRwzpRhE4AOSQt4zTQYjIuW0":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},54183,867218,[],"https://ystcdn.venuertc.com/medical/ystApp/PNv1JgZKMO3NbzWop7HvWPziztZOf4zJ.png","吕昭宝","聊城市第二人民医院","甲状腺乳腺外科","主治医师",183,0,"乳腺癌1期化疗用药详解——安全用药一点通","","https://ystcdn.venuertc.com/venue/AI/cce6a470-6578-40e0-b3ec-add426aa6d34.jpg","\u003Cdiv id=\"material_title\" class=\"breastchemo-title\">乳腺癌1期化疗用药详解——安全用药一点通\u003C/div>\n\n\u003Cdiv class=\"breastchemo-section\">\n  \u003Cdiv class=\"breastchemo-section-header breastchemo-bg01\">🔬 01. 药品概览：常见化疗药及其作用机制\u003C/div>\n  \u003Cdiv class=\"breastchemo-section-content\">\n    说起乳腺癌患者术后常用的化疗药物，像多柔比星脂质体、环磷酰胺、蛋白结合型紫杉醇（白蛋白紫杉醇）和卡铂，这些其实都是肿瘤患者常听说的名字。\n    \u003Cul>\n    \u003Cli>\u003Cb>多柔比星脂质体\u003C/b>属于蒽环类抗生素，主要通过干扰肿瘤细胞的DNA合成与修复，从而阻断分裂增殖。\u003C/li>\n    \u003Cli>\u003Cb>环磷酰胺\u003C/b>是烷化剂类药物，通过生成活性代谢物，破坏癌细胞DNA结构，使细胞无法继续繁殖。\u003C/li>\n    \u003Cli>\u003Cb>白蛋白紫杉醇\u003C/b>属于紫杉烷类，通过影响微管蛋白，阻断细胞有丝分裂。\u003C/li>\n    \u003Cli>\u003Cb>卡铂\u003C/b>为铂类化疗药，通过与DNA结合，阻止肿瘤细胞复制和修复。\u003C/li>\n    \u003C/ul>\n    正因这些药物的联合应用，可达到抑制多条生长通路、最大限度杀灭异常细胞的目的。\u003Cbr>\n    临床数据显示，乳腺癌患者使用以多柔比星、环磷酰胺、紫杉醇和卡铂等组成的方案，辅助治疗后的有效率可达约60%-70%（Swain et al., 2006）。但作用机制不同，具体副作用和注意事项也不同，下文会一一为您介绍。\u003Csup>[1]\u003C/sup> \n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"breastchemo-section\">\n  \u003Cdiv class=\"breastchemo-section-header breastchemo-bg02\">💊 02. 化疗药品的正确使用方法\u003C/div>\n  \u003Cdiv class=\"breastchemo-section-content\">\n    合理使用化疗药物需要掌握以下几个关键要点：\n    \u003Cul>\n      \u003Cli>\n        \u003Cb>给药途径：\u003C/b> 以上常用化疗药均采用静脉滴注方式，不能口服或肌注。化疗必须由专业医疗人员在具备急救条件的环境下操作。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>用药周期：\u003C/b> 多柔比星脂质体+环磷酰胺方案一般为每21天1次，连用4个周期。白蛋白紫杉醇与卡铂也通常为每3周1次，周期数视方案而定。请严格遵医嘱进行，每次按时按量，不可随意中断、调整或提前。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>辅助药物合理搭配：\u003C/b> 化疗常伴用止吐药（如昂丹司琼、阿瑞吡坦），预防胃肠道不适。同时会使用通便药防止便秘。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>饮食与化疗行为：\u003C/b> 化疗并不要求特殊禁食，但应保证均衡饮食、充足饮水，避免刺激性食品。部分药物滴注当日不建议进食高脂肪重口味餐饮。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>不自行加减剂量：\u003C/b> 病人不能根据自我感觉增减药物剂量，漏服、过量任何一种化疗药均需即时联系医生处理。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cb>正确做法：\u003C/b> 每次化疗均应由专人评估安全性，确认实验室指标后方可进行。化疗当天，务必记录体重（用于计算剂量）。\n    \u003Cdiv class=\"breastchemo-tip\">案例：一位60岁女性患者使用紫杉醇和卡铂联合治疗，每次均由静脉输入，且因化疗耐受良好，无不良反应出现，疗程得以顺利完成。\u003C/div>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"breastchemo-section\">\n  \u003Cdiv class=\"breastchemo-section-header breastchemo-bg03\">📦 03. 剂型特点与使用技巧\u003C/div>\n  \u003Cdiv class=\"breastchemo-section-content\">\n    \u003Cul>\n      \u003Cli>\n        \u003Cb>多柔比星脂质体\u003C/b>：为脂质体注射剂，外观为红色溶液，只能静脉滴注，速率需严格控制，避免漏出血管外（会导致局部组织损害）。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>环磷酰胺\u003C/b>：为注射液或冻干粉末型，由护士配制后静滴给药。要求逐步滴注，加快速度可能引发膀胱黏膜损伤等不良反应。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>白蛋白紫杉醇\u003C/b>：为白色乳浊液，不需防过敏预处置，相比普通紫杉醇更安全。使用专用悬浮液静滴，不能与其他药物混合同瓶输入。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>卡铂\u003C/b>：为透明无色液体，静脉滴注方式。用药前需监测肾功能，如有肾功能障碍须调整剂量。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>正确操作技巧\u003C/b>：所有药物必须由专业护士配制和输入，不得自行处理或私自静滴。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cb>特别提醒：\u003C/b> 静脉灌注期间，患者如感到注射部位疼痛、红肿，应立刻告知护士暂停操作排查。\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"breastchemo-section\">\n  \u003Cdiv class=\"breastchemo-section-header breastchemo-bg04\">⚠️ 04. 用药人群注意事项与禁忌\u003C/div>\n  \u003Cdiv class=\"breastchemo-section-content\">\n    \u003Cb>常见适应人群：\u003C/b> \n    \u003Cul>\n      \u003Cli>完成手术的乳腺癌患者，需辅助化疗者；\u003C/li>\n      \u003Cli>体检指标符合条件，无严重心、肝、肾功能异常者。\u003C/li>\n    \u003C/ul>\n    \u003Cb>用药禁忌：\u003C/b>\n    \u003Cul>\n      \u003Cli>对多柔比星脂质体、环磷酰胺、紫杉醇、卡铂成分过敏者禁用该药。\u003C/li>\n      \u003Cli>孕妇和哺乳期女性需慎重，通常不建议使用（除非医生权衡利弊后明确允许）。\u003C/li>\n      \u003Cli>如有严重肝肾功能减退者，部分药物需减量或换药。\u003C/li>\n      \u003Cli>白细胞、血小板严重低下、活动性感染时，应暂停化疗。\u003C/li>\n    \u003C/ul>\n    \u003Cb>特殊人群管理：\u003C/b>\n    \u003Cul>\n      \u003Cli>老年人（65岁以上）用药时需结合体能状况，化疗前最好测定肝、肾、心功能；\u003C/li>\n      \u003Cli>青少年及儿童非适应症，不做常规推荐。\u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"breastchemo-tip\">案例：某位70岁老年患者化疗期间因肾功能降低，医生调整了卡铂剂量，顺利预防了不良反应。\u003C/div>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"breastchemo-section\">\n  \u003Cdiv class=\"breastchemo-section-header breastchemo-bg05\">🔗 05. 化疗中药物相互作用解析\u003C/div>\n  \u003Cdiv class=\"breastchemo-section-content\">\n    化疗药品相互作用复杂，需特别小心。常见组合方案已临床验证安全，但在实际用药中还会遇到以下情况：\n    \u003Cul>\n      \u003Cli>\n        \u003Cb>多柔比星脂质体与其他蒽环类药物\u003C/b>合用时，心脏毒性风险加重，须严格禁用重复蒽环类药物。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>紫杉醇（含白蛋白型）\u003C/b>与顺铂/卡铂联合用药时，需保证先用紫杉醇，再用铂类，否则会加重骨髓抑制。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>与抗真菌药、抗生素等\u003C/b>并用，有些药物能影响化疗药代谢（如酮康唑会增强紫杉醇毒性），用药前须报备医生。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>止吐药（如昂丹司琼、阿瑞吡坦）\u003C/b>和化疗药物之间有固定的联合顺序和间隔，避免影响化疗药清除。\u003C/li>\n    \u003C/ul>\n    \u003Cb>建议：\u003C/b> 服用任何新药或补充剂前，务必告知主管医生；不要自行更换药品或合用新药。\n    \u003Cdiv class=\"breastchemo-tip\">案例：有患者化疗期间服用葡萄柚汁，导致白蛋白紫杉醇代谢受抑，提高了药物毒性。明确：化疗期间忌食葡萄柚等与药物代谢相关的食物。\u003C/div>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"breastchemo-section\">\n  \u003Cdiv class=\"breastchemo-section-header breastchemo-bg06\">🌡️ 06. 常见不良反应及应对建议\u003C/div>\n  \u003Cdiv class=\"breastchemo-section-content\">\n    化疗药物对机体有一定的毒副作用，但大多数可以提前预防和及时处理。常见不良反应及应对方法如下：\n    \u003Cul>\n      \u003Cli>\n        \u003Cb>骨髓抑制\u003C/b>（表现为中性粒细胞低、血小板减少等）是最常见风险。\u003Cbr>\n        \u003Cb>正确做法：\u003C/b> 每轮化疗后定期检查血常规，发现白细胞或血小板显著减少时应延缓下次化疗，严重者加用生长因子或调整剂量。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>恶心、呕吐\u003C/b>多见于给药当日和后数日，通过并用止吐药（昂丹司琼、阿瑞吡坦）可有效缓解。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>脱发\u003C/b>为可逆性副作用，化疗终止后多数患者新发生长。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>神经毒性\u003C/b>（麻木、刺痛、感觉减退等）多与紫杉醇等有关，如感觉明显加重应尽早反馈医生调整方案。\u003C/li>\n      \u003Cli>\n        \u003Cb>肾毒性、心脏毒性\u003C/b>分别见于卡铂、多柔比星类。化疗前需评估肾、心功能，疗程中如有不适应立刻就医。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>其他反应：\u003C/b> 口腔溃疡、皮疹、肝功能异常等。症状明显时随时咨询医疗小组。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cb>特别提醒：\u003C/b> 所有不良反应都应及时向医护人员反馈，切勿自行停药、改药或增减药量。\n    \u003Cdiv class=\"breastchemo-data\">临床资料显示，紫杉醇相关的神经毒性发生率约为60%，但大多中断化疗后可逐步逆转（Rowinsky et al., 1993）。\u003C/div>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"breastchemo-section\">\n  \u003Cdiv class=\"breastchemo-section-header breastchemo-bg07\">📋 07. 储存、用药安全和过量应对\u003C/div>\n  \u003Cdiv class=\"breastchemo-section-content\">\n    \u003Cul>\n      \u003Cli>\n        \u003Cb>储存条件：\u003C/b> 多柔比星脂质体、白蛋白紫杉醇等药需置于阴凉（2-8℃）避光环境，不可冷冻。开瓶后应当日用完，剩余药品不得再次使用。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>用药安全警示：\u003C/b> 化疗药物均属高毒性药物，患者本人及同住成员应避免直接接触药品原液及废弃物，尽量由医护人员处理所有用过的针具、输液袋等。\u003C/li>\n      \u003Cli>\n        \u003Cb>漏服或过量处理：\u003C/b> 化疗方案由医护团队统一安排，不存在普通口服药那种补服问题。若无意间多使用、打错药，必须立刻汇报医护，由医生处理。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cb>正确做法：\u003C/b> 家中从不私自留用任何剩余化疗针剂、注射液；疑似药品变质、过期随时送交医疗部门处置。\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"breastchemo-section breastchemo-summary\">\n  \u003Cdiv class=\"breastchemo-section-header breastchemo-bg08\">🔑 总结与安全提醒\u003C/div>\n  \u003Cdiv class=\"breastchemo-section-content\">\n    简单回顾，乳腺癌化疗常用药物如多柔比星脂质体、环磷酰胺、白蛋白紫杉醇与卡铂，每一种在作用机制、给药方法、不良反应等方面都有需要严格遵循的标准。始终牢记：\u003Cbr>\n    \u003Cb>一是不随意调整用药方案，二是化疗期间有任何不适必须及时反馈医护团队。\u003C/b>\u003Cbr>\n    合理安排化疗时间、遵守储存安全、规范操作，一切以谨慎和安全为首要原则。如有用药疑问，应当和医生详细沟通，避免自行决策。安全用药是每一位患者康复之路的关键守护者。💪\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"breastchemo-section breastchemo-reference\">\n  \u003Cdiv class=\"breastchemo-section-header breastchemo-bg09\">📚 参考资料（部分文献见内容注释）\u003C/div>\n  \u003Cdiv class=\"breastchemo-section-content\">\n    \u003Cul>\n      \u003Cli>[1] Swain, S. M., Jeong, J. H., Geyer Jr, C. E., Costantino, J. P., Pajon, E. R., Fehrenbacher, L., ... & Wolmark, N. (2006). Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. \u003Ci>New England Journal of Medicine\u003C/i>, 355(6), 653-665.\u003C/li>\n      \u003Cli>Rowinsky, E. K., Cazenave, L. A., & Donehower, R. C. (1993). Taxol: a novel investigational antimicrotubule agent. \u003Ci>Journal of the National Cancer Institute\u003C/i>, 85(5), 374-388.\u003C/li>\n      \u003Cli>National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Breast Cancer. Version 1.2024. \u003Ca href=\"https://www.nccn.org/\">https://www.nccn.org/\u003C/a> \u003C/li>\n      \u003Cli>Darby, S. C., McGale, P., Taylor, C. W., & Peto, R. (2011). Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. \u003Ci>The Lancet Oncology\u003C/i>, 12(8), 779-786.\u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\u003C/div>\n\n\u003Cstyle>\n.breastchemo-title {\n  font-size: 32px;\n  color: #267ac9;\n  margin: 40px 0 30px 0;\n  text-align: center;\n  font-weight: bold;\n  letter-spacing: 2px;\n}\n\n.breastchemo-section {\n  margin: 30px auto;\n  max-width: 850px;\n  background: #fff;\n  border-radius: 14px;\n  box-shadow: 0 1px 10px 0 rgba(90,110,140,0.06);\n  padding-bottom: 20px;\n}\n.breastchemo-section-header {\n  font-size: 22px;\n  font-weight: 600;\n  padding: 22px 34px;\n  border-top-left-radius: 14px;\n  border-top-right-radius: 14px;\n  background-repeat: no-repeat;\n  background-size: 100% 120px;\n}\n.breastchemo-bg01 {\n  background-color: #ecf2fa;\n  background-image: linear-gradient(82deg, #e5ecfa 28%, #bcdef9 102%);\n}\n.breastchemo-bg02 {\n  background-color: #f7ada8;\n  background-image: linear-gradient(86deg, #fdf4ee 22%, #ffe3dd 100%);\n}\n.breastchemo-bg03 {\n  background-color: #c9eed6;\n  background-image: linear-gradient(94deg, #e7f2ea 8%, #d3f0e1 98%);\n}\n.breastchemo-bg04 {\n  background-color: #fee9db;\n  background-image: linear-gradient(100deg, #fffbe8 23%, #f5e2da 95%);\n}\n.breastchemo-bg05 {\n  background-color: #e5ecf3;\n  background-image: linear-gradient(110deg, #d8e2f2 46%, #dadbf7 94%);\n}\n.breastchemo-bg06 {\n  background-color: #fce6f7;\n  background-image: linear-gradient(102deg, #fff2fa 32%, #fae1ee 92%);\n}\n.breastchemo-bg07 {\n  background-color: #f3f3fc;\n  background-image: linear-gradient(90deg, #f9faff 17%, #e8e3f7 92%);\n}\n.breastchemo-bg08 {\n  background-color: #f8f6ea;\n  background-image: linear-gradient(95deg, #f3eee4 57%, #e9ecd8 99%);\n}\n.breastchemo-bg09 {\n  background-color: #eaf3fd;\n  background-image: linear-gradient(85deg, #f0f5fa 33%, #d8ecfa 99%);\n}\n\n.breastchemo-section-content {\n  font-size: 18px;\n  line-height: 2.05;\n  color: #2e4051;\n  padding: 28px 34px 16px 34px;\n}\n\n.breastchemo-section-content ul {\n  margin: 16px 0 20px 20px;\n  padding: 0 0 0 10px;\n}\n.breastchemo-section-content ul li {\n  margin-bottom: 9px;\n}\n\n.breastchemo-tip {\n  background: #f1f4fc;\n  border-left: 6px solid #85bbea;\n  padding: 14px 18px;\n  margin: 20px 0 0 0;\n  border-radius: 7px;\n  font-size: 17px;\n  color: #345c82;\n}\n\n.breastchemo-data {\n  background: #fffbea;\n  border-left: 6px solid #e5b549;\n  padding: 14px 18px;\n  margin: 15px 0 8px 0;\n  font-size: 16px;\n  color: #715b40;\n  border-radius: 7px;\n}\n\n.breastchemo-summary {\n  border: 2px solid #91c3e6;\n  margin-top: 45px;\n}\n\n.breastchemo-reference ul {\n  margin-left: 18px;\n  font-size: 16px;\n  color: #213861;\n  padding-bottom: 12px;\n}\n.breastchemo-reference li {\n  margin-bottom: 7px;\n}\n\n@media (max-width: 600px) {\n  .breastchemo-section, .breastchemo-section-header, .breastchemo-section-content {\n    max-width: 98% !important;\n    padding-left: 5px !important;\n    padding-right: 5px !important;\n    font-size: 15px !important;\n  }\n  .breastchemo-title {\n    font-size: 24px;\n    margin: 20px 0 15px 0;\n  }  \n}\n\u003C/style>\n","\u003Cdiv id=\"material_title\" class=\"breastchemo-title\">乳腺癌1期化疗用药详解——安全用药一点通\u003C/div>\n\n\u003Cdiv class=\"breastche",518,"2025-07-30 10:44:15","乳腺癌, 化疗药, 安全用药, 多柔比星, 紫杉醇, 环磷酰胺, 卡铂, 副作用, 用药禁忌, 治疗方案","详细解析乳腺癌1期化疗常用药物及其作用机制，指导患者安全用药，合理安排化疗方案，确保有效应对不良反应，维持身体健康。","2025-07-30 21:26:00",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]